Press Releases

LAFAYETTE, Louisiana, Oct. 15, 2019 /PRNewswire/ -- RedHawk Holdings Corp. (OTC: SNDD) ("RedHawk" or the "Company") a diversified holding company engaged in sales and distribution of medical devices, branded generic pharmaceutical drugs, commercial real estate investment and leasing, point of entry full-body security systems, and specialized financial

CURIOX BIOSYSTEMS, is an A*STAR spinoff company, that develops bioinstrumentation solutions used in cell analysis and therapy for the pharmaceutical and biotech industries. The company has successfully penetrated the USA, PRC, Korean and European markets and also secured a Series B funding of US$15M from Korean biotech

GENEVA, Oct. 15, 2019 /PRNewswire/ -- Asia accounted for more than two-thirds of all patent, trademark and industrial design applications in 2018, with China driving overall growth in demand for intellectual property (IP) rights as the United States of America (U.S.) mainta

MEXICO CITY, Oct. 15, 2019 /PRNewswire/ -- Genomma Lab cordially invites you to join its quarterly conference call to discuss results for the third quarter of 2019. Presenters:

SAN CARLOS, Calif., Oct. 15, 2019 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of

AUSTIN, Texas, Oct. 15, 2019 /PRNewswire/ -- The Texas Hemp Industries Association (TXHIA) will be hosting a two-day conference on October 20-22 at the

LIBBY, Mont., Oct. 15, 2019 /PRNewswire/ -- The Center for Asbestos Related Disease (CARD Clinic) in Libby, Montana, began screening for lung cancer using low-dose CT scans in 2013. In conjunction with International Early Lung Cancer Action Program (I-ELCAP), the program was developed to identify lung cancers at their earliest and most cu

SAN DIEGO, Oct. 15, 2019 /PRNewswire/ -- Denovo Biopharma LLC, a pioneer in applying precision medicine to develop innovative therapies, today announced FDA's approval to initiate Denovo's Phase 2b clinical study of DB102 in patients with newly-diagnosed glioblastoma (GBM) in combination with radiation and temozolomide.

Q3 2019 Revenue of $16.5 million, Adjusted EBITDA of $9.8 million, and Net income of $5.9 million  KELOWNA, BC, Oct. 15, 2019 /PRNewswire/ - Valens GroWorks Corp. (TSXV: VGW) (OTC: VGWCF) (the "Company" or "Valens

NASHVILLE, Tenn., Oct. 15, 2019 /PRNewswire/ -- The National Health Care Anti-Fraud Association (NHCAA) today announced that Sara "Sally" A